Literature DB >> 27158342

Neoalbaconol inhibits cell growth of human cholangiocarcinoma cells by up-regulating PTEN.

Guang-Yao Zhou1, Chen-Wei Pan1, Ling-Xiang Jin1, Jian-Jian Zheng2, Yong-Xiang Yi3.   

Abstract

The recently isolated small-molecule neoalbaconol (NA) from Albatrellus confluens has been suggested to possess the ability to inhibit cell growth of many cancer cells. In this study, we investigated the role of NA in the regulation of cell apoptosis in human cholangiocarcinoma cell lines both in vitro and in vivo. Our results indicate that NA could induce cancer cell death via the AKT pathway by targeting phosphorate and tension homolog detected on chromosome 10 (PTEN) and supported the feasibility of NA being a novel chemotherapeutic treatment for human cholangiocarcinoma.

Entities:  

Keywords:  Neoalbaconol; PTEN; cholangiocarcinoma

Year:  2016        PMID: 27158342      PMCID: PMC4846899     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  33 in total

1.  The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway.

Authors:  Min Fang; Zhirong Shen; Song Huang; Liping Zhao; She Chen; Tak W Mak; Xiaodong Wang
Journal:  Cell       Date:  2010-11-11       Impact factor: 41.582

Review 2.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

3.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas.

Authors:  Keisuke Kurose; Kristie Gilley; Satoshi Matsumoto; Peter H Watson; Xiao-Ping Zhou; Charis Eng
Journal:  Nat Genet       Date:  2002-10-15       Impact factor: 38.330

4.  Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice.

Authors:  Xiaoling Xu; Shogo Kobayashi; Wenhui Qiao; Cuiling Li; Cuiying Xiao; Svetlana Radaeva; Bangyan Stiles; Rui-Hong Wang; Nobuya Ohara; Tadashi Yoshino; Derek LeRoith; Michael S Torbenson; Gregory J Gores; Hong Wu; Bin Gao; Chu-Xia Deng
Journal:  J Clin Invest       Date:  2006-06-08       Impact factor: 14.808

5.  Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7).

Authors:  Anders Sundqvist; Maria T Bengoechea-Alonso; Xin Ye; Vasyl Lukiyanchuk; Jianping Jin; J Wade Harper; Johan Ericsson
Journal:  Cell Metab       Date:  2005-06       Impact factor: 27.287

6.  Subtle variations in Pten dose determine cancer susceptibility.

Authors:  Andrea Alimonti; Arkaitz Carracedo; John G Clohessy; Lloyd C Trotman; Caterina Nardella; Ainara Egia; Leonardo Salmena; Katia Sampieri; William J Haveman; Edi Brogi; Andrea L Richardson; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

7.  The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

Authors:  Joon-Yong Chung; Seung-Mo Hong; Byeong Yeob Choi; Hyungjun Cho; Eunsil Yu; Stephen M Hewitt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.

Authors:  Yasuo Horie; Akira Suzuki; Ei Kataoka; Takehiko Sasaki; Koichi Hamada; Junko Sasaki; Katsunori Mizuno; Go Hasegawa; Hiroyuki Kishimoto; Masahiro Iizuka; Makoto Naito; Katsuhiko Enomoto; Sumio Watanabe; Tak Wah Mak; Toru Nakano
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

9.  MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer.

Authors:  Gui-Ming Zhang; Chun-Yang Bao; Fang-Ning Wan; Da-Long Cao; Xiao-Jian Qin; Hai-Liang Zhang; Yao Zhu; Bo Dai; Guo-Hai Shi; Ding-Wei Ye
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

Review 10.  Advances in diagnosis and treatment of hilar cholangiocarcinoma -- a review.

Authors:  Geng Zhimin; Hidayatullah Noor; Zheng Jian-Bo; Wang Lin; Rajiv Kumar Jha
Journal:  Med Sci Monit       Date:  2013-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.